								Sh	<u>eet 1 c</u>)f	
FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				1 '	ATTY. DO ABX-PF/2	APPLN. NO. 10/038,591					
INFORMATION DISCLOSURE					APPLICA Bruce D.	CONF NO. 1	IRMAT 445	199	_		
FEB 0 7 2003 STATEMENT BY APPLICANT					FILING D	1642			דם ד		
TRADE!	A.P.									ح. ح	
	,	UNITED STA	TES. PATENT	DOC	UMENTS	· · · · · · · · · · · · · · · · · · ·			<u>-</u> g_	7	
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLAS	S F	FILING DAGE IF 66 APPROPRIAT		E	
	6,084,085	July 4, 2000	Baserga et al.		536	23.5					
		FOREIGN	N PATENT DOC	UME	NTS						
EXAMINER	DOCUMENT NUMBER	DATE	COUNTRY	C	LASS	SUBCLASS	TRANSLATION				
INITIAL					LAGO	00002700	Y	ES	NO)	
Lly	WO 00/50067	August 31, 2000	PCT		_						
	OTHER DO	CUMENTS (Includi	ing Author, Titl	e, Da	te, Pertir	nent Pages, Etc	:.)				
EXAMINER INITIAL										大大大	
LA	DiGiovanni, John, et al., "Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice," <u>Proc. Natl. Acad. Sci. USA</u> , 97:3455-3460 (2000).										
	Drexhage, H.A. Medicine, 45:28	& Wulffraat, N.N 35-293 (1994).	1., "Endocrine	auto	immune	diseases," Net	herland	ls Jour	nal of	•	
	Kim, Bhumsoo, et al., "Insulin receptor substrate 2 and shc play different roles in insulin-like growth factor I signaling," <u>Journal of Biological Chemistry</u> , 273:34543-34550 (1998).										
	Smith, Lois E., et al., "Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor," Nature Medicine, 5:1390-1395 (1999).										
		appy, Luc, et al., "Antibodies to insulin-like growth factor I receptors in diabetes and other sorders," <u>Diabetes</u> , 37:1708-1714 (1988).									
	Thompson, Kathleen, et al., "Low prevalence of autoantibodies to the insulin-like growth factor I receptor in children with short stature," <u>Pediatric Research</u> , 32:455-459 (1992).										
V	Weightman, David R., et al., "Autoantibodies to IGF-1 binding sites in thyroid associated opthalmopathy," <u>Autoimmunity</u> , 16:251-257 (1993).										
) 700	_ :	opher, et al., "Rev	•		~ .	-		•			

EXAMINER

(2000).

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.